Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 12, 2026, by Ultragenyx Pharmaceutical Inc. The filing serves to announce preliminary unaudited financial results for the fiscal year ended December 31, 2025. The Company expects to report its full year audited results in February 2026.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing specific preliminary data. However, the text of this 8-K form does not provide clear values for the following metrics:
- Total fiscal year 2025 revenue
- Revenue for Crysvita®
- Revenue for Dojolvi®
- Cash and investments at fiscal year end
- Profit, cash flow, margins, or debt levels
Investors must refer to the attached Press Release (Exhibit 99.1) for these specific figures.
Material Changes and Outlook
The filing does not detail material changes versus prior periods or provide specific guidance, risks, or management commentary within the body of the 8-K text. The primary purpose is to disclose the timing of the preliminary announcement and the upcoming full-year report in February 2026.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual preliminary revenue and cash figures.
- Verify the specific revenue breakdown between Crysvita® and Dojolvi®.
- Monitor the upcoming full-year earnings release scheduled for February 2026 for audited results.
- Confirm the Company's liquidity position based on the cash and investments data in the press release.